ストックスクリーナーアプリを入手
0.74
1.11%
-0.0083
プレマーケット:
.74
Inmed Pharmaceuticals Inc (INM) 最新ニュース
InMed Pharmaceuticals Reprices Investment Options to Attract Capital - TipRanks
InMed Pharmaceuticals Amends Preferred Investment Options - TMX Newsfile
InMed Pharmaceuticals Reprices Sabby and Wainwright Investment Options to $0.80 - TradingView
[8-K] InMed Pharmaceuticals Inc. Reports Material Event - Stock Titan
Sabby, Wainwright option deals reset InMed exercise prices to $0.80 - Stock Titan
Is InMed (INM) stock gaining momentum (Smart Money Flows) 2026-04-18Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Fund Flows: Is InMed Pharmaceuticals Inc in a long term uptrend2026 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Income Plays: Is InMed Pharmaceuticals Inc in a long term uptrend2026 Market Trends & Verified Momentum Stock Alerts - baoquankhu1.vn
InMed Pharmaceuticals Inc. Files Form 8-K Current Report with SEC – Company Information, Nasdaq Listing, and Legal Opinion Included - Minichart
Price performance - Yahoo Finance Singapore
Published on: 2026-04-05 13:17:10 - baoquankhu1.vn
InMed Pharmaceuticals files prospectus supplement for at-the-market share offering - Investing.com
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing - TipRanks
InMed Pharmaceuticals files prospectus supplement for ATM share sales under amended sales agreement - TradingView — Track All Markets
InMed (NASDAQ: INM) files ATM prospectus supplement under S-3 shelf - Stock Titan
InMed Pharmaceuticals (NASDAQ: INM) files $1.21M ATM offering with 3.0% fee - Stock Titan
[EFFECT] InMed Pharmaceuticals Inc. SEC Filing - Stock Titan
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
InMed receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com Australia
InMed warned by Nasdaq over minimum bid price non-compliance - TipRanks
InMed Pharmaceuticals Notified of Nasdaq Non-Compliance with $1 Minimum Bid Price Rule - geneonline.com
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Investing News Network
InMed receives Nasdaq minimum bid price deficiency notice - Investing.com
InMed Pharma gets Nasdaq non-compliance notice - MSN
InMed Pharmaceuticals Inc.Common Shares (NQ: INM - The Chronicle-Journal
InMed Pharmaceuticals Reports Positive INM-901 Data in Human Brain Organoid Models for Alzheimer’s Disease Program 12 - Minichart
InMed reports preclinical data on Alzheimer’s drug candidate By Investing.com - Investing.com Australia
InMed Pharmaceuticals Inc. (INM) Stock: Shows Promising Anti-Inflammatory Effects in 3D Brain Organoid Study - parameter.io
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with N - GuruFocus
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Investing News Network
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate - TipRanks
InMed reports preclinical data on Alzheimer’s drug candidate - Investing.com
InMed Pharmaceuticals Inc recently released positive research data for its Alzheimer's disease treatment project INM-901, according to documents submitted to the U.S. Securities and Exchange Commission (SEC). - Bitget
InMed (NASDAQ: INM) reports INM-901 organoid data, targets Phase 1 in 2027 - Stock Titan
Aug Decliners: Can InMed Pharmaceuticals Inc outperform under higher oil pricesWeekly Market Outlook & Low Drawdown Trading Strategies - baoquankhu1.vn
[S-3] InMed Pharmaceuticals Inc. Shelf Registration Statement - Stock Titan
Aug Weekly: Can InMed Pharmaceuticals Inc be the next market leaderBear Alert & Accurate Entry/Exit Alerts - baoquankhu1.vn
Ideas Watch: Can InMed Pharmaceuticals Inc be the next market leader2026 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Published on: 2026-03-17 19:00:00 - baoquankhu1.vn
CEO Moves: Will InMed Pharmaceuticals Inc stock go up in YEAR2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
InMed Pharmaceuticals Advances INM-901 for Alzheimer’s and INM-089 for Macular Degeneration with FDA Engagement Planned for 2026-2027 1 - Minichart
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
InMed Pharmaceuticals (INM) Sets 2026 Development Goals - gurufocus.com
InMed Provides Update on Pharmaceutical Development ProgramsAdvancing Lead Drug Candidates Towards IND and Clinical Trial - Investing News Network
InMed outlines 2026 development plans for lead programs - TipRanks
InMed Provides 2026 Development Outlook; Targets FDA pre-IND for INM-901 and Phase 1 in 2027 - TradingView
InMed (INM) sets 2026 goals for Alzheimer’s and eye-disease drug programs - Stock Titan
InMed's 2026 push to bring Alzheimer's, eye drug candidates to human testing - Stock Titan
Can InMed Pharmaceuticals Inc reach all time highs this yearJuly 2025 Technicals & Weekly Momentum Picks - baoquankhu1.vn
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline - Investing News Network
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):